Výsledky vyhledávání

Akademický článek

FOXP1 and KLF2 reciprocally regulate checkpoints of stem-like to effector transition in CAR T cells.

Autor: Zhu Z; Department of Immunology, University of Texas Southwestern Medical Center, Dallas, TX, USA.; Immunology Ph.D. Program, University of Texas Southwestern Medical Center, Dallas, TX, USA., Lou G; Department of Immunology and Microbiology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA., Teng XL; Department of Immunology, University of Texas Southwestern Medical Center, Dallas, TX, USA., Wang H; Department of Immunology, University of Texas Southwestern Medical Center, Dallas, TX, USA., Luo Y; Department of Immunology, University of Texas Southwestern Medical Center, Dallas, TX, USA., Shi W; Department of Immunology and Microbiology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA., Yihunie K; Department of Immunology, University of Texas Southwestern Medical Center, Dallas, TX, USA., Hao S; Department of Immunology, University of Texas Southwestern Medical Center, Dallas, TX, USA., DeGolier K; Department of Immunology and Microbiology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.; Department of Pediatrics, University of Colorado Anschutz Medical Campus, Aurora, CO, USA., Liao C; Department of Pathology, University of Texas Southwestern Medical Center, Dallas, TX, USA., Huang H; Department of Surgery, University of Texas Southwestern Medical Center, Dallas, TX, USA., Zhang Q; Department of Pathology, University of Texas Southwestern Medical Center, Dallas, TX, USA.; Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX, USA., Fry T; Department of Pediatrics, University of Colorado Anschutz Medical Campus, Aurora, CO, USA., Wang T; Quantitative Biomedical Research Center, Peter O'Donnell Jr. School of Public Health, University of Texas Southwestern Medical Center, Dallas, TX, USA.; Center for the Genetics of Host Defense, University of Texas Southwestern Medical Center, Dallas, TX, USA., Yao C; Department of Immunology, University of Texas Southwestern Medical Center, Dallas, TX, USA. chen.yao@utsouthwestern.edu.; Kidney Cancer Program, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX, USA. chen.yao@utsouthwestern.edu., Wu T; Department of Immunology, University of Texas Southwestern Medical Center, Dallas, TX, USA. tuoqi.wu@utsouthwestern.edu.; Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX, USA. tuoqi.wu@utsouthwestern.edu.

Publikováno v: Nature immunology [Nat Immunol] 2024 Jan; Vol. 25 (1), pp. 117-128. Date of Electronic Publication: 2023 Nov 27.

Zobrazit plný text záznamu

Akademický článek

Prospective PTCTC trial of myeloablative haplo-BMT with posttransplant cyclophosphamide for pediatric acute leukemias.

Autor: Fierro-Pineda JC; Department of Oncology and the Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD.; Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD., Tsai HL; Department of Oncology and the Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD., Blackford A; Department of Oncology and the Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD., Cluster A; Division of Pediatric Hematology/Oncology, Washington University in St. Louis, St. Louis, MO., Caywood E; Nemours Center for Cancer and Blood Disorders, Nemours Children's Health, Wilmington, DE; Department of Pediatrics, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA., Dalal J; Division of Pediatric Hematology/Oncology/Bone Marrow Transplant, Rainbow Babies and Children's Hospital, Case Western Reserve University, Cleveland, OH., Davis J; Division of Hematology/Oncology/BMT, Department of Pediatrics, BC Children's Hospital, University of British Columbia, Vancouver, BC., Egeler M; Hospital for Sick Children, Toronto, Canada., Huo J; Pediatric Blood and Marrow Transplant and Cellular Therapies, Atrium Health Levine Children's Hospital, Charlotte, NC., Hudspeth M; Division of Pediatric Hematology, Oncology, and BMT, Medical University of South Carolina, Charleston, SC., Keating A; Pediatric Blood and Marrow Transplant and Cellular Therapeutics, University of Colorado School of Medicine, and The Children's Hospital of Colorado, Denver, CO., Kelly SS; AdventHealth for Children, Orlando, FL., Krueger J; Division of Hematology/Oncology, Bone Marrow Transplant/Cell Therapy Section, SickKids, Toronto, ON, Canada., Lee D; Division of Hematology, Oncology, and BMT, Nationwide Children's Hospital and Department of Pediatrics, The Ohio State University College of Medicine, Columbus, OH., Lehmann L; Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Harvard Medical School, Boston, MA., Madden L; Texas Transplant Institute, San Antonio, TX., Oshrine B; Cancer and Blood Disorders Institute, Johns Hopkins All Children's Hospital, Saint Petersburg, FL., Pulsipher MA; Intermountain Primary Children's Hospital Division of Hematology, Oncology, and BMT, Huntsman Cancer Institute, Spencer Fox Eccles School of Medicine at the University of Utah, Salt Lake City, UT., Fry T; Pediatric Blood and Marrow Transplant and Cellular Therapeutics, University of Colorado School of Medicine, and The Children's Hospital of Colorado, Denver, CO., Symons HJ; Department of Oncology and the Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD.

Publikováno v: Blood advances [Blood Adv] 2023 Sep 26; Vol. 7 (18), pp. 5639-5648.

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání